Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study-Reference-Cited by-同舟云学术

Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study

Published:2024-06-11 Issue: Volume: Page:1-11
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hong Danhua¹,Yin Mengzhuo¹^ORCID,Li Jie¹^ORCID,Deng Zhiyong¹^ORCID,Ren Zhilei¹,Zhou Yun¹,Huang Shuijin¹,Yan Xuejun¹²,Zhong Weijie¹,Liu Feng¹,Yang Chongzhe¹^ORCID

Affiliation:

1. Department of Geriatrics, School of Medicine, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, China

2. School of Medicine, Institute of Clinical Medicine, Center for Medical Research on Innovation and Translation, Guangzhou First People’s Hospital, South China University of Technology, Guangzhou, China

Funder

National Natural Science Foundation of China

China International Medical Foundation

Guangzhou Planned Project of Science and Technology

Guangzhou Key Discipline of Medicine

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2364830

Reference37 articles.

1. National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: non-Hodgkin lymphoma; 2023 [cited 2023 Mar 1]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html

2. Diffuse Large B-Cell Lymphoma

3. Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults;Xavier AC;Am J Hematol,2018

4. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis

5. Surveillance Research Program. National Cancer Institute SEER*Stat Software Version 8.4.0.1; 2023 [cited 2023 Feb 20]. Available from: www.seer.cancer.gov/seerstat